These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 29190319

  • 1. Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer.
    de Boer SM, Wortman BG, Bosse T, Powell ME, Singh N, Hollema H, Wilson G, Chowdhury MN, Mileshkin L, Pyman J, Katsaros D, Carinelli S, Fyles A, McLachlin CM, Haie-Meder C, Duvillard P, Nout RA, Verhoeven-Adema KW, Putter H, Creutzberg CL, Smit VTHBM, for PORTEC Study Group.
    Ann Oncol; 2018 Feb 01; 29(2):424-430. PubMed ID: 29190319
    [Abstract] [Full Text] [Related]

  • 2. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
    de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL, PORTEC study group.
    Lancet Oncol; 2018 Mar 01; 19(3):295-309. PubMed ID: 29449189
    [Abstract] [Full Text] [Related]

  • 3. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
    de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Kitchener HC, Nijman HW, Kruitwagen RF, Nout RA, Verhoeven-Adema KW, Smit VT, Putter H, Creutzberg CL, PORTEC study group.
    Lancet Oncol; 2016 Aug 01; 17(8):1114-1126. PubMed ID: 27397040
    [Abstract] [Full Text] [Related]

  • 4. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
    de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Gribaudo S, Provencher D, Hanzen C, Kruitwagen RF, Smit VTHBM, Singh N, Do V, Lissoni A, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL, PORTEC Study Group.
    Lancet Oncol; 2019 Sep 01; 20(9):1273-1285. PubMed ID: 31345626
    [Abstract] [Full Text] [Related]

  • 5. Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer.
    Milgrom SA, Kollmeier MA, Abu-Rustum NR, Tew WP, Sonoda Y, Barakat RR, Alektiar KM.
    Gynecol Oncol; 2013 Sep 01; 130(3):436-40. PubMed ID: 23800696
    [Abstract] [Full Text] [Related]

  • 6. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.
    Bosse T, Peters EE, Creutzberg CL, Jürgenliemk-Schulz IM, Jobsen JJ, Mens JW, Lutgens LC, van der Steen-Banasik EM, Smit VT, Nout RA.
    Eur J Cancer; 2015 Sep 01; 51(13):1742-50. PubMed ID: 26049688
    [Abstract] [Full Text] [Related]

  • 7. NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer.
    Viswanathan AN, Moughan J, Miller BE, Xiao Y, Jhingran A, Portelance L, Bosch WR, Matulonis UA, Horowitz NS, Mannel RS, Souhami L, Erickson BA, Winter KA, Small W, Gaffney DK.
    Cancer; 2015 Jul 01; 121(13):2156-63. PubMed ID: 25847373
    [Abstract] [Full Text] [Related]

  • 8. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results.
    Bosse T, Nout RA, Stelloo E, Dreef E, Nijman HW, Jürgenliemk-Schulz IM, Jobsen JJ, Creutzberg CL, Smit VT.
    Eur J Cancer; 2014 Oct 01; 50(15):2602-10. PubMed ID: 25126672
    [Abstract] [Full Text] [Related]

  • 9. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial.
    Wortman BG, Bosse T, Nout RA, Lutgens LCHW, van der Steen-Banasik EM, Westerveld H, van den Berg H, Slot A, De Winter KAJ, Verhoeven-Adema KW, Smit VTHBM, Creutzberg CL, PORTEC Study Group.
    Gynecol Oncol; 2018 Oct 01; 151(1):69-75. PubMed ID: 30078506
    [Abstract] [Full Text] [Related]

  • 10. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials.
    Creutzberg CL, van Stiphout RG, Nout RA, Lutgens LC, Jürgenliemk-Schulz IM, Jobsen JJ, Smit VT, Lambin P.
    Int J Radiat Oncol Biol Phys; 2015 Mar 01; 91(3):530-9. PubMed ID: 25680597
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer.
    Chapman BV, Swanick CW, Ning MS, Allen PK, Soliman PT, Westin SN, Pardeshi V, Broaddus RR, Lu KH, Jhingran A, Eifel PJ, Klopp AH.
    Gynecol Oncol; 2019 Jul 01; 154(1):22-28. PubMed ID: 31109659
    [Abstract] [Full Text] [Related]

  • 12. [Radiochemotherapy improves failure-free survival in stage III endometrial cancer : Final results of the PORTEC-3 trial].
    Krug D, Arians N.
    Strahlenther Onkol; 2017 Dec 01; 193(12):1070-1071. PubMed ID: 28905089
    [No Abstract] [Full Text] [Related]

  • 13. Carboplatin (every 21 days) and divided-dose paclitaxel (days 1, 11): rationale and tolerance in chemotherapy naïve women with high-grade epithelial cancers of Mullerian origin.
    Kudlowitz D, Velastegui A, Musa F, Muggia F.
    Cancer Chemother Pharmacol; 2018 May 01; 81(5):847-851. PubMed ID: 29516152
    [Abstract] [Full Text] [Related]

  • 14. Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology).
    Mustea A, Koensgen D, Belau A, Sehouli J, Lichtenegger W, Schneidewind L, Sommer H, Markmann S, Scharf JP, Ehmke M, Ledwon P, Braicu I, Zygmunt M, Koehler G.
    Cancer Chemother Pharmacol; 2013 Nov 01; 72(5):975-83. PubMed ID: 23995698
    [Abstract] [Full Text] [Related]

  • 15. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
    Duska LR, Berkowitz R, Matulonis U, Muto M, Goodman A, McIntyre JF, Klein A, Atkinson T, Seiden MV, Campos S.
    Gynecol Oncol; 2005 Jan 01; 96(1):198-203. PubMed ID: 15589601
    [Abstract] [Full Text] [Related]

  • 16. Concurrent cisplatin/radiation followed by adjuvant cisplatin/paclitaxel in treatment of patients with stage IB grade 3, IC and IIA endometrial carcinoma.
    Foad I, Sharawy I, Mostafa E, Margergis M, Hussein T.
    J Egypt Natl Canc Inst; 2007 Jun 01; 19(2):163-9. PubMed ID: 19034346
    [Abstract] [Full Text] [Related]

  • 17. The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma.
    Jutzi L, Hoskins P, Lim P, Aquino-Parsons C, Tinker A, Kwon JS.
    Gynecol Oncol; 2013 Dec 01; 131(3):581-5. PubMed ID: 24055614
    [Abstract] [Full Text] [Related]

  • 18. Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach.
    Lupe K, Kwon J, D'Souza D, Gawlik C, Stitt L, Whiston F, Nascu P, Wong E, Carey MS.
    Int J Radiat Oncol Biol Phys; 2007 Jan 01; 67(1):110-6. PubMed ID: 17084542
    [Abstract] [Full Text] [Related]

  • 19. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W, Choy H.
    Lancet Oncol; 2015 Feb 01; 16(2):187-99. PubMed ID: 25601342
    [Abstract] [Full Text] [Related]

  • 20. A multi-institutional analysis of sequential versus 'sandwich' adjuvant chemotherapy and radiotherapy for stage IIIC endometrial carcinoma.
    Onal C, Sari SY, Yildirim BA, Yavas G, Gultekin M, Guler OC, Akyurek S, Yildiz F.
    J Gynecol Oncol; 2019 May 01; 30(3):e28. PubMed ID: 30887753
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.